{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:49:15Z","timestamp":1771649355551,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Project of Administration of Traditional Chinese Medicine of Jiangsu Province of China","award":["YB201805"],"award-info":[{"award-number":["YB201805"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent studies have confirmed that combined surgery and anti-TNF therapy could improve outcomes in patients with perianal fistulising Crohn\u2019s disease (PFCD). However, the optimal timing for infliximab infusion after surgical intervention is uncertain. We aimed to determine the long-term efficacy of early initiation of infliximab following surgery among PFCD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a retrospective cohort study of PFCD patients who received combined infliximab and surgical treatment between 2010 and 2018 at a tertiary referral hospital. Patients were grouped according to the time interval between surgery and infliximab infusion, with &lt;\u20096\u00a0weeks into early infliximab induction group and &gt;\u20096\u00a0weeks into delayed infliximab induction group. The primary outcome was to compare surgical re-intervention between early and delayed infliximab induction groups. The secondary outcomes were fistula healing and predictors associated with these outcomes of early infliximab induction approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred and seventeen patients were included (73 in early infliximab induction, 44 in delayed infliximab induction). The median interval between surgery and infliximab initiation was 9.0 (IQR 5.5\u201317.0) days in early infliximab induction group and 188.0 (IQR 102.25\u2013455.75) days in delayed infliximab induction group. After followed-up for a median of 36\u00a0months, 61.6% of patients in early infliximab induction group and 65.9% in delayed infliximab induction group attained fistula healing (<jats:italic>p<\/jats:italic>\u2009=\u20090.643). The cumulative re-intervention rate was 23%, 32%, 34% in early infliximab induction group and 16%, 25%, 25% in delayed infliximab induction group, at 1, 2, and 3\u00a0years respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.235). Presence of abscess at baseline (HR\u2009=\u20095.283; 95% CI, 1.61\u201317.335; <jats:italic>p<\/jats:italic>\u2009=\u20090.006) and infliximab maintenance therapy &gt;\u20093 infusions (HR\u2009=\u20093.691; 95% CI, 1.233\u201311.051; <jats:italic>p<\/jats:italic>\u2009=\u20090.02) were associated with re-intervention in early infliximab induction group. Presence of abscess at baseline also negatively influenced fistula healing (HR\u2009=\u20093.429, 95% CI, 1.216\u20139.668; <jats:italic>p<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although no clear benefit was shown compared with delayed infliximab induction group, early initiation of infliximab after surgery could achieve promising results for PFCD patients. Before infliximab infusion, durable drainage is required for patients with concomitant abscess or prolonged infliximab maintenance therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-02078-9","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T13:03:58Z","timestamp":1641819838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn\u2019s disease: a retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3977-193X","authenticated-orcid":false,"given":"Ping","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-fei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-4085","authenticated-orcid":false,"given":"Bo-lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"issue":"7","key":"2078_CR1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/DCR.0b013e31825228b0","volume":"55","author":"TW Eglinton","year":"2012","unstructured":"Eglinton TW, Barclay ML, Gearry RB, Frizelle FA. The spectrum of perianal Crohn\u2019s disease in a population-based cohort. Dis Colon Rectum. 2012;55(7):773\u20137.","journal-title":"Dis Colon Rectum"},{"issue":"12","key":"2078_CR2","first-page":"1392","volume":"12","author":"WY Mak","year":"2018","unstructured":"Mak WY, Mak OS, Lee CK, Tang W, Leung WK, Wong MTL, Sze ASF, Li M, Leung CM, Lo FH, Lam BCY, Chan KH, Shan EHS, Tsang SWC, Hui AJ, Chow WH, Chan FKL, Sung JJY, Ng S. Significant medical and surgical morbidity in perianal Crohn\u2019s disease: results from a territory-wide study. J Crohn\u2019s Colitis. 2018;12(12):1392\u20138.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"2","key":"2078_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","volume":"11","author":"P Gionchetti","year":"2017","unstructured":"Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 2\u2014surgical management and special situations on behalf of ECCO. J Crohn\u2019s Colitis. 2017;11(2):135\u201349.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"9","key":"2078_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350(9):876\u201385.","journal-title":"N Engl J Med"},{"issue":"9","key":"2078_CR5","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1136\/gutjnl-2013-306709","volume":"63","author":"KB Gecse","year":"2014","unstructured":"Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn\u2019s disease. Gut. 2014;63(9):1381\u201392.","journal-title":"Gut"},{"issue":"2","key":"2078_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00054725-200303000-00003","volume":"9","author":"M Regueiro","year":"2003","unstructured":"Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn\u2019s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9(2):98\u2013103.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"2078_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10350-004-6611-4","volume":"46","author":"DR Topstad","year":"2003","unstructured":"Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn\u2019s disease. Dis Colon Rectum. 2003;46(5):577\u201383.","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"2078_CR8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jamcollsurg.2016.05.017","volume":"223","author":"CS Choi","year":"2016","unstructured":"Choi CS, Berg AS, Sangster W, Schieffer KM, Harris LR 3rd, Deiling SM, Koltun WA. Combined medical and surgical approach improves healing of septic perianal Crohn\u2019s disease. J Am Coll Surg. 2016;223(3):506-14.e1.","journal-title":"J Am Coll Surg"},{"issue":"12","key":"2078_CR9","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s10350-006-0656-5","volume":"49","author":"SA Hyder","year":"2006","unstructured":"Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn\u2019s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49(12):1837\u201341.","journal-title":"Dis Colon Rectum"},{"issue":"10","key":"2078_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.1463-1318.2012.02944.x","volume":"14","author":"G El-Gazzaz","year":"2012","unstructured":"El-Gazzaz G, Hull T, Church JM. Biological immunomodulators improve the healing rate in surgically treated perianal Crohn\u2019s fistulas. Colorectal Dis. 2012;14(10):1217\u201323.","journal-title":"Colorectal Dis"},{"issue":"2","key":"2078_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1463-1318.2012.03124.x","volume":"15","author":"R Antakia","year":"2013","unstructured":"Antakia R, Shorthouse AJ, Robinson K, Lobo AJ. Combined modality treatment for complex fistulating perianal Crohn\u2019s disease. Colorectal Dis. 2013;15(2):210\u20136.","journal-title":"Colorectal Dis"},{"issue":"7","key":"2078_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/apt.12906","volume":"40","author":"NA Yassin","year":"2014","unstructured":"Yassin NA, Askari A, Warusavitarne J, Faiz OD, Athanasiou T, Phillips RK, Hart AL. Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;40(7):741\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2078_CR13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/codi.13311","volume":"18","author":"EJ de Groof","year":"2016","unstructured":"de Groof EJ, Sahami S, Lucas C, Ponsioen CY, Bemelman WA, Buskens CJ. Treatment of perianal fistula in Crohn\u2019s disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment. Colorectal Dis. 2016;18(7):667\u201375.","journal-title":"Colorectal Dis"},{"issue":"3","key":"2078_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/codi.13462","volume":"19","author":"MJ Lee","year":"2017","unstructured":"Lee MJ, Heywood N, Sagar PM, Brown SR, Fearnhead NS, pCD Collaborators. Surgical management of fistulating perianal Crohn\u2019s disease: a UK survey. Colorectal Dis. 2017;19(3):266\u201373.","journal-title":"Colorectal Dis"},{"issue":"5","key":"2078_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/codi.13672","volume":"19","author":"MJ Lee","year":"2017","unstructured":"Lee MJ, Heywood N, Sagar PM, Brown SR, Fearnhead NS, ACPGBI Perianal Crohn\u2019s Disease Group. Association of Coloproctology of Great Britain and Ireland consensus exercise on surgical management of fistulating perianal Crohn\u2019s disease. Colorectal Dis. 2017;19(5):418\u201329.","journal-title":"Colorectal Dis"},{"issue":"4","key":"2078_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113(4):481\u2013517.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2078_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/MIB.0000000000000315","volume":"21","author":"DA Schwartz","year":"2015","unstructured":"Schwartz DA, Ghazi LJ, Regueiro M, Fichera A, Zoccali M, Ong EM, Mortel\u00e9 KJ. Guidelines for the multidisciplinary management of Crohn\u2019s perianal fistulas: summary statement. Inflamm Bowel Dis. 2015;21(4):723\u201330.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2078_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ibd.21405","volume":"17","author":"P Roumegu\u00e8re","year":"2011","unstructured":"Roumegu\u00e8re P, Bouchard D, Pigot F, Castinel A, Juguet F, Gaye D, Capdepont M, Zerbib F, Laharie D. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn\u2019s disease: results from a prospective study. Inflamm Bowel Dis. 2011;17(1):69\u201376.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"2078_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s10350-004-0828-0","volume":"48","author":"SJ van der Hagen","year":"2005","unstructured":"van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets-Tan RG, van Gemert WG. Anti-TNF-\u03b1 (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn\u2019s disease: a preliminary report. Dis Colon Rectum. 2005;48(4):758\u201367.","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"2078_CR20","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.3748\/wjg.v21.i8.2475","volume":"21","author":"BL Yang","year":"2015","unstructured":"Yang BL, Chen YG, Gu YF, Chen HJ, Sun GD, Zhu P, Shao WJ. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn\u2019s disease. World J Gastroenterol. 2015;21(8):2475\u201382.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2078_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/codi.12851","volume":"17","author":"A Haennig","year":"2015","unstructured":"Haennig A, Staumont G, Lepage B, Faure P, Alric L, Buscail L, Bournet B, Moreau J. The results of seton drainage combined with anti-TNF\u03b1 therapy for anal fistula in Crohn\u2019s disease. Colorectal Dis. 2015;17(4):311\u20139.","journal-title":"Colorectal Dis"},{"issue":"5","key":"2078_CR22","first-page":"299","volume":"53","author":"G Sciaudone","year":"2010","unstructured":"Sciaudone G, Di Stazio C, Limongelli P, Guadagni I, Pellino G, Riegler G, Coscione P, Selvaggi F. Treatment of complex perianal fistulas in Crohn disease: Infliximab, surgery or combined approach. Can J Surg. 2010;53(5):299\u2013304.","journal-title":"Can J Surg"},{"issue":"11","key":"2078_CR23","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s10350-007-9077-3","volume":"50","author":"WB Gaertner","year":"2007","unstructured":"Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP. Does infliximab infusion impact results of operative treatment for Crohn\u02bcs perianal fistulas? Dis Colon Rectum. 2007;50(11):1754\u201360.","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"2078_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.cgh.2012.12.042","volume":"11","author":"G Bouguen","year":"2013","unstructured":"Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Long-term outcome of perianal fistulizing Crohn\u2019s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11(8):975\u201381.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2078_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/flgastro-2017-100866","volume":"9","author":"MJ Lee","year":"2018","unstructured":"Lee MJ, Brown SR, Fearnhead NS, Hart A, Lobo AJ, PCD Collaborators. How are we managing fistulating perianal Crohn\u2019s disease? Results of a national survey of consultant gastroenterologists. Frontline Gastroenterol. 2018;9(1):16\u201322.","journal-title":"Frontline Gastroenterol"},{"issue":"5","key":"2078_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","volume":"125","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice Committee. American gastroenterological association technical review on perianal Crohn\u2019s disease. Gastroenterology. 2003;125(5):1508\u201330.","journal-title":"Gastroenterology"},{"issue":"35","key":"2078_CR27","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","volume":"23","author":"A Vasudevan","year":"2017","unstructured":"Vasudevan A, Gibson PR, Van Langenberg DR. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told\u202f? World J Gastroenterol. 2017;23(35):6385\u2013402.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"2078_CR28","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1111\/j.1572-0241.2000.03363.x","volume":"95","author":"RD Cohen","year":"2000","unstructured":"Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn\u2019s disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95(12):3469\u201377.","journal-title":"Am J Gastroenterol"},{"issue":"9317","key":"2078_CR29","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet"},{"key":"2078_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s13063-015-0831-x","volume":"16","author":"EJ de Groof","year":"2015","unstructured":"de Groof EJ, Buskens CJ, Ponsioen CY, et al. Multimodal treatment of perianal fistulas in Crohn\u2019s disease: seton versus anti-TNF versus advancement plasty (PISA)\u2014study protocol for a randomized controlled trial. Trials. 2015;16:366.","journal-title":"Trials"},{"issue":"2","key":"2078_CR31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/gutjnl-2017-315503","volume":"68","author":"K Sahnan","year":"2019","unstructured":"Sahnan K, Tozer PJ, Adegbola SO, et al. Developing a core outcome set for fistulising perianal Crohn\u2019s disease. Gut. 2019;68(2):226\u201338.","journal-title":"Gut"},{"issue":"9","key":"2078_CR32","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/apt.14969","volume":"48","author":"S Sebastian","year":"2018","unstructured":"Sebastian S, Black C, Pugliese D, et al. The role of multimodal treatment in Crohn\u2032s disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018;48(9):941\u201350.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"2078_CR33","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1007\/s10620-008-0545-y","volume":"54","author":"D Tougeron","year":"2009","unstructured":"Tougeron D, Savoye G, Savoye-Collet C, Koning E, Michot F, Lerebours E. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn\u2019s disease. Dig Dis Sci. 2009;54(8):1746\u201352.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"2078_CR34","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/j.1463-1318.2011.02811.x","volume":"14","author":"S Duff","year":"2012","unstructured":"Duff S, Sagar PM, Rao M, Dolling S, Sprakes M, Hamlin PJ. Infliximab and surgical treatment of complex anal Crohn\u2019s disease. Colorectal Dis. 2012;14(8):972\u20136.","journal-title":"Colorectal Dis"},{"issue":"12","key":"2078_CR35","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/ajg.2009.509","volume":"104","author":"SC Ng","year":"2009","unstructured":"Ng SC, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, Kamm MA. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn\u2019s perineal fistulas. Am J Gastroenterol. 2009;104(12):2973\u201386.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2078_CR36","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/ibd.21940","volume":"18","author":"P Tozer","year":"2012","unstructured":"Tozer P, Ng SC, Siddiqui MR, Plamondon S, Burling D, Gupta A, Swatton A, Tripoli S, Vaizey CJ, Kamm MA, Phillips R, Hart A. Long-term MRI-guided combined anti-TNF-a and thiopurine therapy for Crohn\u2019s perianal fistulas. Inflamm Bowel Dis. 2012;18(10):1825\u201334.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2078_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/SLA.0b013e3181e61df5","volume":"252","author":"DW Jones","year":"2010","unstructured":"Jones DW, Finlayson SR. Trends in surgery for Crohn\u2019s disease in the era of infliximab. Ann Surg. 2010;252(2):307\u201312.","journal-title":"Ann Surg"},{"issue":"8","key":"2078_CR38","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/MEG.0000000000000651","volume":"28","author":"V Chhaya","year":"2016","unstructured":"Chhaya V, Saxena S, Cecil E, Subramanian V, Curcin V, Majeed A, Pollok RC. Emerging trends and risk factors for perianal surgery in Crohn\u2019s disease: a 20-year national population-based cohort study. Eur J Gastroenterol Hepatol. 2016;28(8):890\u20135.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"2078_CR39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","volume":"23","author":"BE Sands","year":"2006","unstructured":"Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn\u2019s disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006;23(8):1127\u201336.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2078_CR40","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1136\/gutjnl-2019-320553","volume":"70","author":"SO Adegbola","year":"2021","unstructured":"Adegbola SO, Dibley L, Sahnan K, et al. Development and initial psychometric validation of a patient-reported outcome measure for Crohn\u2019s perianal fistula: the Crohn\u2019s Anal Fistula Quality of Life (CAF-QoL) scale. Gut. 2021;70(9):1649\u201356.","journal-title":"Gut"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-02078-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-02078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T13:06:22Z","timestamp":1641819982000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-02078-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2078"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-02078-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Ethics Committee of the Affiliated Hospital of Nanjing University of Chinese Medicine (2017NL-049-02). Written informed consent was obtained from all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}